Small intestine bacterial overgrowth

King CE, Toskes PP Small intestine bacterial overgrowth. Gastroenterology 1979 76 1035— 1055. 

Riordan SM, Mclver CJ, Walker BM, Dun-combe VM, Bolin TD, Thomas MC The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996 91 1795-1803. 

Nelis GF, Engelage AH, Samson G Does longterm inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth Neth J Med 1994 45 93-100. 

Shindo K, Machida M, Miyakawa K, Fukumura M A syndrome of cirrhosis, achlorhydria, small intestinal bacterial overgrowth, and fat malabsorption. Am J Gastroenterol 1993 88 2084-2091. 

Stotzer PO, Bjornsson ES, Abrahamsson H Interdigestive and postprandial motility in small intestinal bacterial overgrowth. Scand J Gastroenterol 1996,31 875-880. 

Riordan SM, Mclver CJ, Wakefield D, Bolin TD, Duncombe VM, Thomas MC Small intestinal bacterial overgrowth in the symptomatic elderly. Am J Gastroenterol 1997 92 47-51. 

Di Stefano M, Corazza GR Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. Chemotherapy 2005 51(suppl 1) 103-109. 

Lin HC Small intestinal bacterial overgrowth A framework for understanding irritable bowel syndrome. JAMA 2004 292 852-858. 

Strid H, Simren M, Stotzer PO, Ringstrom G, Abrahamsson H, Bjornsson ES Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion 2003 67 129-137. 

Rifaximin Rifamycin Antibiotic Gut bacteria Enteric infection Diarrhea, infectious Hepatic encephalopathy Small intestine bacterial overgrowth Inflammatory bowel disease Colonic diverticular disease Irritable bowel syndrome Constipation Clostridium difficile infection Helicobacter pylori infection Colorectal surgery Bowel decontamination, selective Pancreatitis, acute Bacterial peritonitis, spontaneous Nonsteroidal anti-inflammatory drug enteropathy... 

Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, Gasbarrini G Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. He-patogastroenterology 2002 49 1582-1586. 

Bouhnik Y, Alain S, Attar A, Flourie B, Ras-kine L, Sanson-Le Pors MJ, Rambaud JC Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999 94 1327-1331. 

Corazza GR, Ventrucci M, Strocchi A, Sorge M, Pranzo L, Pezzilli R, Gasbarrini G Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res 1988 16 312-316. 

Treatment of Small Intestine Bacterial Overgrowth and Related Symptoms by Rifaximin... 

Rifaximin Small intestine bacterial overgrowth Therapy Nonabsorbable antibiotics... 

The treatment of small intestine bacterial overgrowth (SIBO) is a clinical challenge for physicians, as data contained in the peer review literature do not offer conclusive... 

Su J, Smith MB, Rerknimitr R, Morrow D Small intestine bacterial overgrowth presenting as protein-losing enteropathy. Dig Dis Sci 1998 43 679-681. 

Banwell JG, Kistel LA, Giannella RA, Weber FL, Lieber A, Powell DE Small intestine bacterial overgrowth syndrome. Gastroenterology 1981 80 834-845. 

Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR Rifaximin versus chlortetracy-cline in the short-term treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2000 14 551-556. 

Attar A, Flourie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea A crossover, randomized trial. Gastroenterology 1999 i 17 794— 797. 

Di Stefano M, Pezzimenti D, Veneto G, Missa-nelli A, Corazza GR Absorbable vs. nonabsorbable antibiotics in the therapy of small intestine bacterial overgrowth (SIBO) in patients with blind loop syndrome. Dig Liver Dis 2001 33 A93. 

Pimentel H, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000 95 3503-3506. 

Process for treating small intestine bacterial overgrowth in animals Patent number US57766524 (1998)... 

Small intestinal bacterial overgrowth 50 mg s.c. q.d. for 3 weeks VIPoma-associated diarrhea 150-750 meg s.c./i.v. divided in b.i.d.-q.i.d. dose for 2 weeks, then titrate for response... 

Small intestinal bacterial overgrowth 400 mg p.o. t.i.d. for 2 weeks. Therapy may be repeated if required... 

Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010 8 504-8. 

A comparison between two commercial delayed release peppermint oil preparations found that there were differences in the pharmacokinetics in relation to bioavailability times and release site. A capsule that is more effective in delivering the peppermint oil to the distal small intestine and ascending colon would be more bene cial in the treatment of irritable bowel syndrome (White et al., 1987). It has also been suggested that the con icting results in some trials may be due to the inclusion of patients suffering from lactose intolerance, syndrome of small intestinal bacterial overgrowth, and celiac disease, all of which have symptoms similar to irritable bowel disease (Cappello et al., 2007). 

Logan, A. C., Beaulne, T. M, 2002, The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil A case report, Altem. Med. Rev. 7 410-417,... 

---